Term Sheet

The latest on private equity, M&A, deals and movements — from Wall Street to Silicon Valley

PharMEDium sale a big deal for Oak

January 29, 2014: 1:41 PM ET

download (2)Source: Pharmacy compounding company valued at $900 million.

FORTUNE -- Private equity firm Clayton Dubilier & Rice today said that it has completed its previously-announced acquisition of a majority stake in PharMEDium from Oak Investment Partners and Baird Capital.

No financial terms were disclosed, but Fortune has learned that the deal was done at around a $900 million enterprise valuation.

For Oak this represents around a 6x return on its 2007 investment, when it paid around $67 million to acquire an equity stake from Baird (which retained part of its position).

PharMEDium is a Lake Forrest, Ill.–based provider of hospital pharmacy sterile compounding services.

Sign up for Dan Primack's daily email newsletter on deals and deal-makers: GetTermSheet.com

Join the Conversation
About This Author
Dan Primack
Dan Primack
Senior Editor, Fortune

Dan Primack joined Fortune.com in September 2010 to cover deals and dealmakers, from Wall Street to Sand Hill Road. Previously, Dan was an editor-at-large with Thomson Reuters, where he launched both peHUB.com and the peHUB Wire email service. In a past journalistic life, Dan ran a community paper in Roxbury, Massachusetts. He currently lives just outside of Boston.

Email a Tip | @danprimack | RSS
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Powered by WordPress.com VIP.